Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC
Baseline CTC counts were shown to be strong indicators for subsequent therapy response and 2-year progression-free survival. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Amir Goldkorn, MD Source Type: news
Karen H. Lu, MD, on Addresses Gap in Genetic Counseling for Women at Risk for Ovarian Cancer
The MD Anderson Cancer Center expert spoke about the disconnect in women who are at risk for ovarian cancer to actually receive genetic counseling. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: undefined Source Type: news
FDA Approves Ramucirumab Injection in Combination with Erlotinib for NSCLC
The FDA approved ramucirumab injection in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 mutations. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Teclistamab Shows Promise for Patients with Relapsed/Refractory Myeloma
Teclistamab appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma, according to a phase I study presented at the ASCO Virtual Scientific Program. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news
Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease –Associated Kidney Cancer
The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease –associated renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news
Study Finds No Benefit to Surgery, Radiation in De Novo Stage IV Breast Cancer
Women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumor with the expectation of a survival benefit, according to results from the ECOG-ACRIN E2108 trial. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Jason Harris Source Type: news
Carfilzomib Triplet Therapy Shows Inferior PFS in Newly Diagnosed Multiple Myeloma
Carfilzomib combined with lenalidomide and dexamethasone failed to improve progression-free survival, compared with the current standard of care triplet of bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Jessica Skarzynski Source Type: news
Algorithm Matches Pediatric Patients with Cancer to Precision Medicines
Utilizing data from the INFORM registry, researchers were able to identify high level priority targets in pediatric patients with cancer utilizing an algorithm that matched them to targeted treatments extending their progression-free survival time and showing the feasibility of this program in a real-world setting. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Conor Killmurray Source Type: news
Petros Grivas, MD, PhD, on the Future of the CCC19 Registry
Data from the COVID-19 and Cancer Consortium registry, presented at the 2020 ASCO Annual Virtual Science Program, reported how the COVID-19 pandemic has impacted patients with cancer thus far. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Petros Grivas, MD, PhD Source Type: news
Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma
A phase III study presented the 2020 ASCO Virtual Scientific Program showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news
Phase II Trial Finds LuPSMA May be Effective for Men with mCRPC
The results, presented at the 2020 ASCO Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer who were previously treated with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Zanubrutinib Appears to be Safe, Effective for Waldenstr öm Macroglobulinemia
According to the largest phase III trial examining BTK inhibitors for patients with Waldenstr öm macroglobulinemia, zanubrutinib appears to be associated with higher complete response or very good partial response, as well as clinically meaningful advantages in safety and tolerability compared to ibrutinib. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news
Addition of Selinexor to Bortezomib, Dexamethasone Improves Responses in Myeloma
The addition of selinexor, a selective inhibitor of nuclear export, to bortezomib and dexamethasone improved progression-free survival across all subgroups in a study of pretreated patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Beth Fand Incollingo Source Type: news
FDA Approves Atezolizumab/Bevacizumab Combination for HCC
The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
